



DEPARTMENT OF THE AIR FORCE  
HEADQUARTERS UNITED STATES AIR FORCE  
WASHINGTON, DC

JAN 22 2001

MEMORANDUM FOR HQ AFMC/SGP HQ USAFE/SGPA HQ AFRC/SGP  
HQ AETC/SGP HQ AIA/SG HQ AMC/SGPA  
HQ AFSPC/SG HQ ACC/SGPA HQ PACAF/SGPA  
ANG/SGP HQ AFSOC/SGPA HQ USAFA/SGP  
AFMSA/CC HQ AFPC/DPAM USAFSAM/CC/FEC  
11 MDG/CC

FROM: HQ AFMOA/SGZA  
110 Luke Avenue, Room 400  
Bolling AFB, DC 20332-7050

SUBJECT: Aircrew Waiverable Medications - Xalatan

Effective immediately, Xalatan (latanoprost) is approved for use in aircrew as a second-line drug for the treatment of glaucoma. Xalatan may be employed as a second-line drug only and in accordance with the following restrictions:

a. Therapy with a topical beta-blocker combined with Propine fails to achieve the desired target intraocular pressure or the aviator is intolerant of one or both of these other classes of drugs.

b. Aeromedical Consultation Service (ACS) evaluation is required for rated aircrew (pilots, navigators, and flight surgeons); record review in lieu of evaluation is allowed for Flying Class III. In these cases, the ACS will determine the required history, examination, and test results to be provided for their review. Either the ACS or the referring MAJCOM may request in-person ACS evaluation for Class III individuals if indicated.

c. Aircrew will be DNIF pending ACS evaluation/review.

Waiver authority is MAJCOM.

If you have any questions please contact AFMOA/SGZA, 110 Luke Avenue, Room 405, Bolling AFB, DC 20332-7050 at DSN 297-4200. POCs are Col Arleen Saenger, Col Dan Eldredge or MSgt Anthony Labonte.

ARLEEN M. SAENGER, Col, USAF, MC, CFS  
Chief, Physical Standards  
Air Force Medical Operations Agency  
Office of the Surgeon General

cc:  
HQ AFIA/SGP  
HSW/CC